Theratechnologies Receives FDA Approval For EGRIFTA WR (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy
ReutersMar 25, 2025 9:47 PM
March 25 (Reuters) - Theratechnologies Inc TH.TO:
THERATECHNOLOGIES RECEIVES FDA APPROVAL FOR EGRIFTA WR™ (TESAMORELIN F8) TO TREAT EXCESS VISCERAL ABDOMINAL FAT IN ADULTS WITH HIV AND LIPODYSTROPHY
THERATECHNOLOGIES INC: EGRIFTA WR WILL BE MANUFACTURED AT A NEW, U.S.-BASED CONTRACT DRUG MANUFACTURING ORGANIZATION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Invest in the “Magnificent Seven” in 2026? One Stock or All of Them?
TradingKey - The Magnificent Seven defined markets in 2024 and remained at the heart of the 2025 story. Collectively, they have unparalleled control over AThe Magnificent Seven includes Nvidia (NVDA), Apple (AAPL), Alphabet (GOOG) (GOOGL), Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META), andTradingKey
13 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
